On May 17, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the FPI in the Phase Ib/II clinical study of first domestic SIRPα-Fc fusion protein targeting human CD47 (project number: IMM01) combined with PD-1 antibody for relapsed and refractory malignant tumors (clinical research project number: IMM01-04). The first subject was enrolled and dosed successfully.

On April 1, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Frank Xiaodong Gan was appointed as the senior vice president of our Company in April 2022, and is responsible for clinical development of our Group in the United States.

On March 30, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Xu, Wencheng as the vice president of clinical operations.

On March 28, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that data from 2 different new projects in two posters will be presented at the 2022 annual meeting of American Association for Cancer Research (AACR) hold in New Orleans from April 8 to 13.

On March 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared the appointment of Dr. Lu Qiying was appointed as the chief medical officer and senior vice president of our Company in March 2022, and is responsible for formulating the clinical strategy and direct clinical development of our Group.